The case for antifungal stewardship

Michelle R. Ananda-Rajah*, Monica Slavin, Karin T. Thursky

*Corresponding author for this work

    Research output: Contribution to journalReview ArticleResearchpeer-review

    72 Citations (Scopus)

    Abstract

    PURPOSE OF REVIEW: Antimicrobial stewardship (AMS) has overwhelmingly focussed on antibiotics while antifungal agents have been largely neglected despite the few published audits of antifungal drug use demonstrating clear deficiencies in prescribing behaviour. In this review, we outline not only the elements of antifungal stewardship (AFS) in common with AMS but also features specific to antifungal drugs, combined with insights from our experience in AFS. RECENT FINDINGS: Invasive fungal diseases (IFDs) have a lower institutional incidence relative to infections caused by multiresistant bacteria, but their health and economic burden are substantial. Pharmacy costs inclusive of antifungal agents are a major determinant of IFD-attributable hospital cost. High drug costs and the toxicities of antifungal agents are the principal rationale for AFS while antifungal resistance is an emerging but less prevalent issue. The high mortality/morbidity associated with IFDs, including adverse impact on curative chemotherapy, combined with suboptimal diagnostic tools, has driven the overuse of antifungal drugs. De-escalation of empiric therapy is one of the most challenging aspects of AFS to implement. Nonculture-based tests may enhance AFS, but refinement of both target populations and clinical pathways incorporating their use is required. Performance indicators including structural, process and outcome measures are integral for demonstrating the value of AFS programmes. SUMMARY: Practice guidelines adapted to the local context are the cornerstone of AFS. Local epidemiology informs the choice of antifungal agents for the prevention and management of IFDs, underscoring the need for surveillance. Adherence to minimum standards of prescribing ensures that clinical outcomes are optimized and drug toxicities minimized, thus meeting healthcare quality and safety goals.

    Original languageEnglish
    Pages (from-to)107-115
    Number of pages9
    JournalCurrent Opinion in Infectious Diseases
    Volume25
    Issue number1
    DOIs
    Publication statusPublished - Feb 2012

    Keywords

    • Antifungal agents
    • Antifungal stewardship
    • Fungal infections

    Cite this

    Ananda-Rajah, Michelle R. ; Slavin, Monica ; Thursky, Karin T. / The case for antifungal stewardship. In: Current Opinion in Infectious Diseases. 2012 ; Vol. 25, No. 1. pp. 107-115.
    @article{d1aab76faa9042fcb09c7d5ab5b7bea6,
    title = "The case for antifungal stewardship",
    abstract = "PURPOSE OF REVIEW: Antimicrobial stewardship (AMS) has overwhelmingly focussed on antibiotics while antifungal agents have been largely neglected despite the few published audits of antifungal drug use demonstrating clear deficiencies in prescribing behaviour. In this review, we outline not only the elements of antifungal stewardship (AFS) in common with AMS but also features specific to antifungal drugs, combined with insights from our experience in AFS. RECENT FINDINGS: Invasive fungal diseases (IFDs) have a lower institutional incidence relative to infections caused by multiresistant bacteria, but their health and economic burden are substantial. Pharmacy costs inclusive of antifungal agents are a major determinant of IFD-attributable hospital cost. High drug costs and the toxicities of antifungal agents are the principal rationale for AFS while antifungal resistance is an emerging but less prevalent issue. The high mortality/morbidity associated with IFDs, including adverse impact on curative chemotherapy, combined with suboptimal diagnostic tools, has driven the overuse of antifungal drugs. De-escalation of empiric therapy is one of the most challenging aspects of AFS to implement. Nonculture-based tests may enhance AFS, but refinement of both target populations and clinical pathways incorporating their use is required. Performance indicators including structural, process and outcome measures are integral for demonstrating the value of AFS programmes. SUMMARY: Practice guidelines adapted to the local context are the cornerstone of AFS. Local epidemiology informs the choice of antifungal agents for the prevention and management of IFDs, underscoring the need for surveillance. Adherence to minimum standards of prescribing ensures that clinical outcomes are optimized and drug toxicities minimized, thus meeting healthcare quality and safety goals.",
    keywords = "Antifungal agents, Antifungal stewardship, Fungal infections",
    author = "Ananda-Rajah, {Michelle R.} and Monica Slavin and Thursky, {Karin T.}",
    year = "2012",
    month = "2",
    doi = "10.1097/QCO.0b013e32834e0680",
    language = "English",
    volume = "25",
    pages = "107--115",
    journal = "Current Opinion in Infectious Diseases",
    issn = "0951-7375",
    publisher = "Lippincott Williams & Wilkins",
    number = "1",

    }

    The case for antifungal stewardship. / Ananda-Rajah, Michelle R.; Slavin, Monica; Thursky, Karin T.

    In: Current Opinion in Infectious Diseases, Vol. 25, No. 1, 02.2012, p. 107-115.

    Research output: Contribution to journalReview ArticleResearchpeer-review

    TY - JOUR

    T1 - The case for antifungal stewardship

    AU - Ananda-Rajah, Michelle R.

    AU - Slavin, Monica

    AU - Thursky, Karin T.

    PY - 2012/2

    Y1 - 2012/2

    N2 - PURPOSE OF REVIEW: Antimicrobial stewardship (AMS) has overwhelmingly focussed on antibiotics while antifungal agents have been largely neglected despite the few published audits of antifungal drug use demonstrating clear deficiencies in prescribing behaviour. In this review, we outline not only the elements of antifungal stewardship (AFS) in common with AMS but also features specific to antifungal drugs, combined with insights from our experience in AFS. RECENT FINDINGS: Invasive fungal diseases (IFDs) have a lower institutional incidence relative to infections caused by multiresistant bacteria, but their health and economic burden are substantial. Pharmacy costs inclusive of antifungal agents are a major determinant of IFD-attributable hospital cost. High drug costs and the toxicities of antifungal agents are the principal rationale for AFS while antifungal resistance is an emerging but less prevalent issue. The high mortality/morbidity associated with IFDs, including adverse impact on curative chemotherapy, combined with suboptimal diagnostic tools, has driven the overuse of antifungal drugs. De-escalation of empiric therapy is one of the most challenging aspects of AFS to implement. Nonculture-based tests may enhance AFS, but refinement of both target populations and clinical pathways incorporating their use is required. Performance indicators including structural, process and outcome measures are integral for demonstrating the value of AFS programmes. SUMMARY: Practice guidelines adapted to the local context are the cornerstone of AFS. Local epidemiology informs the choice of antifungal agents for the prevention and management of IFDs, underscoring the need for surveillance. Adherence to minimum standards of prescribing ensures that clinical outcomes are optimized and drug toxicities minimized, thus meeting healthcare quality and safety goals.

    AB - PURPOSE OF REVIEW: Antimicrobial stewardship (AMS) has overwhelmingly focussed on antibiotics while antifungal agents have been largely neglected despite the few published audits of antifungal drug use demonstrating clear deficiencies in prescribing behaviour. In this review, we outline not only the elements of antifungal stewardship (AFS) in common with AMS but also features specific to antifungal drugs, combined with insights from our experience in AFS. RECENT FINDINGS: Invasive fungal diseases (IFDs) have a lower institutional incidence relative to infections caused by multiresistant bacteria, but their health and economic burden are substantial. Pharmacy costs inclusive of antifungal agents are a major determinant of IFD-attributable hospital cost. High drug costs and the toxicities of antifungal agents are the principal rationale for AFS while antifungal resistance is an emerging but less prevalent issue. The high mortality/morbidity associated with IFDs, including adverse impact on curative chemotherapy, combined with suboptimal diagnostic tools, has driven the overuse of antifungal drugs. De-escalation of empiric therapy is one of the most challenging aspects of AFS to implement. Nonculture-based tests may enhance AFS, but refinement of both target populations and clinical pathways incorporating their use is required. Performance indicators including structural, process and outcome measures are integral for demonstrating the value of AFS programmes. SUMMARY: Practice guidelines adapted to the local context are the cornerstone of AFS. Local epidemiology informs the choice of antifungal agents for the prevention and management of IFDs, underscoring the need for surveillance. Adherence to minimum standards of prescribing ensures that clinical outcomes are optimized and drug toxicities minimized, thus meeting healthcare quality and safety goals.

    KW - Antifungal agents

    KW - Antifungal stewardship

    KW - Fungal infections

    UR - http://www.scopus.com/inward/record.url?scp=84155167311&partnerID=8YFLogxK

    U2 - 10.1097/QCO.0b013e32834e0680

    DO - 10.1097/QCO.0b013e32834e0680

    M3 - Review Article

    C2 - 22123667

    AN - SCOPUS:84155167311

    VL - 25

    SP - 107

    EP - 115

    JO - Current Opinion in Infectious Diseases

    JF - Current Opinion in Infectious Diseases

    SN - 0951-7375

    IS - 1

    ER -